| Literature DB >> 28103572 |
Siyu Wu1, Yanyan Zhu2, Zhaozhi Yang3, Miao Mo4, Hongbo Gao5, Wentao Yang6, Guangyu Liu1.
Abstract
A recent randomized controlled trial firstly demonstrated that cavity shaving significantly decreased the rate of positive margins and re-excision among partial mastectomy (PM) patients. However, it remains unknown whether cavity shaving should be routinely applied to Chinese breast cancer patients undergoing PM. A total of 408 PM patients undergoing 410 PMs among 1796 surgically treated breast cancer patients at Fudan University Shanghai Cancer Centre from January 2015 to June 2015 were included in our study. Data were analysed with univariate or multivariate analysis. Overall, 11 of 410 cases (2.7%) had positive margins postoperatively. Moreover, only 24.6% of the cases (P<0.05) presented with ductal carcinoma in situ (DCIS), among whom 10.0% obtained positive margins. In multivariate logistic regression analysis, presence of mammographic calcifications was significantly associated with margin positivity (P<0.05, OR=6.06, 95% CI: 1.53-23.91). In conclusion, cavity shaving during PM should not be routinely performed in Chinese breast cancer patients, particularly in highly selected cases with a low prevalence of DCIS. PM patients with preoperative mammographic calcifications were more likely to have positive margins and might benefit more from cavity shaving.Entities:
Keywords: Chinese; highly selected; low rate; partial mastectomy; positive margins
Mesh:
Year: 2017 PMID: 28103572 PMCID: PMC5355339 DOI: 10.18632/oncotarget.14686
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Clinicopathological characteristics of patients who underwent initial breast-conserving surgery categorised by margin status
| Variable | N (Percent) | Margin status | ||
|---|---|---|---|---|
| Positive | Negative | |||
| >0.05 | ||||
| 46 | 42 | 46 | ||
| 19-82 | 38-77 | 19-82 | ||
| 105 (25.6%) | 3 (2.9%) | 102 (97.1%) | ||
| 305 (74.4%) | 8 (2.6%) | 297 (97.4%) | ||
| >0.05 | ||||
| 60 (14.6%) | 3 (5%) | 57 (95%) | ||
| 350 (85.4%) | 8 (2.3%) | 342 (97.7%) | ||
| <0.05 | ||||
| 110 (26.8%) | 7 (6.4%) | 103 (93.6%) | ||
| 280 (68.3%) | 4 (1.4%) | 276 (98.6%) | ||
| 20 (4.9%) | 0 (0%) | 20 (100%) | ||
| >0.05 | ||||
| 41 (10%) | 0 (0%) | 41 (100%) | ||
| 369 (90%) | 11 (3.0%) | 358 (97.0%) | ||
| 373 (91.0%) | 9 (2.4%) | 364 (97.6%) | ||
| 9 (2.2%) | 0 (0%) | 9 (100%) | ||
| 21 (5.1%) | 2 (9.5%) | 19 (90.5%) | ||
| 7 (1.7%) | 0 (0%) | 7 (100%) | ||
| <0.05 | ||||
| 101 (24.6%) | 10 (10.0%) | 91 (90.0%) | ||
| 309 (75.4%) | 1 (0.3%) | 308 (99.7%) | ||
| >0.05 | ||||
| 1.5 | 1.2 | 1.5 | ||
| 0-4 | 1-3.5 | 0-4 | ||
| 331 (80.7%) | 8 (2.4%) | 323 (97.6%) | ||
| 76 (18.5%) | 2 (2.6%) | 74 (97.4%) | ||
| 3 (0.8%) | 1 (33.3%) | 2 (66.7%) | ||
| >0.05 | ||||
| 93 (22.7%) | 1 (1.1%) | 92 (98.9%) | ||
| 313 (76.3%) | 10 (3.2%) | 303 (96.8%) | ||
| 4 (1.0%) | 0 (0%) | 4 (100%) | ||
| >0.05 | ||||
| 78 (19.0%) | 1 (1.3%) | 77 (98.7%) | ||
| 297 (72.4%) | 10 (3.4%) | 287 (96.6%) | ||
| 35 (8.5%) | 0 (0%) | 35 (100%) | ||
| >0.05 | ||||
| 12 (2.9%) | 0 (0%) | 12 (100%) | ||
| 148 (36.1%) | 2 (1.4%) | 146 (98.6%) | ||
| 140 (34.1%) | 4 (2.9%) | 136 (97.1%) | ||
| 13 (3.2%) | 1 (7.7%) | 12 (92.3%) | ||
| 18 (4.4%) | 1 (5.6%) | 17 (94.4%) | ||
| 12 (2.9%) | 0 (0%) | 12 (100%) | ||
| 67 (16.3%) | 3 (4.5%) | 64 (95.5%) | ||
| 11 (2.7%) | 0 (0%) | 11 (100%) | ||
| >0.05 | ||||
| 111 (27.1%) | 4 (3.6%) | 105 (96.4%) | ||
| 297 (72.4%) | 7 (2.4%) | 290 (97.6%) | ||
| 2 (0.5%) | 0 (0%) | 2 (100%) | ||
| >0.05 | ||||
| 133 (32.4%) | 7 (5.3%) | 126 (94.7%) | ||
| 275 (67.1%) | 4 (1.5%) | 271 (98.5%) | ||
| 2 (0.5%) | 0 (0%) | 2 (100%) | ||
| >0.05 | ||||
| 330 (80.5%) | 9 (2.7%) | 321 (97.3%) | ||
| 76 (18.5%) | 2 (2.6%) | 74 (97.4%) | ||
| 4 (1.0%) | 0 (0%) | 4 (100%) | ||
| >0.05 | ||||
| 204 (49.8%) | 6 (2.9%) | 198 (97.1%) | ||
| 201 (49.0%) | 5 (2.4%) | 196 (97.6%) | ||
| 5 (1.2%) | 0 (0%) | 5 (100%) | ||
NA: not accessed; DCIS: ductal carcinoma in situ; ER: oestrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor-2.
Univariate and multivariate analysis for the factors of positive margins
| Factors | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR(95%CI) | OR (95%CI) | |||
| 1.00 | 1.00 | |||
| 0.92 (0.24-3.50) | 0.90 | 0.67 (0.16-2.78) | 0.59 | |
| 1.00 | 1.00 | |||
| 0.99 (0.21-4.76) | 0.99 | 0.81 (0.16-4.23) | 0.80 | |
| 1.00 | 1.00 | |||
| 3.97 (1.14-13.80) | 0.03 | 6.06 (1.53-23.91) | 0.01 | |
| 1.00 | 1.00 | |||
| 0.42 (0.05-3.39) | 0.42 | 0.47 (0.05-4.52) | 0.51 | |
| 1.00 | 1.00 | |||
| 0.33 (0.04-2.61) | 0.29 | 0.32 (0.04-2.59) | 0.29 | |
| 1.00 | 1.00 | |||
| 0.64 (0.18-2.22) | 0.48 | 0.483 (0.13-1.81) | 0.28 | |
| 1.00 | 1.00 | |||
| 0.95 (0.20-4.49) | 0.95 | 0.755 (0.15-3.86) | 0.74 | |
| 1.00 | 1.00 | |||
| 0.68(0.19-2.44) | 0.55 | 0.874 (0.19-4.10) | 0.86 | |
Correlations between calcification features and margin status
| N=96 | Margin status | ||||
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Calcifications only | 38 (39.6%) | 3 (7.9%) | 35 (92.1%) | >0.05 | |
| Calcifications with mass | 33 (34.4%) | 3 (9.1%) | 30 (90.9%) | ||
| Calcifications with asymmetric compactness | 10 (10.4%) | 1 (10.0%) | 9 (90.0%) | ||
| Calcifications with architectural distortion | 15 (15.6%) | 0 (0%) | 15 (100%) | ||
| Fine branching | 94 (97.9%) | 7 (7.4%) | 87 (92.6%) | >0.05 | |
| Pleomorphic | 2 (2.1%) | 0 (0%) | 2 (100%) | ||
| Clustered | 50 (52.1%) | 6 (12.0%) | 44 (88.0%) | >0.05 | |
| Regional | 4 (4.2%) | 0 (0%) | 4 (100%) | ||
| Linear | 9 (9.4%) | 1 (11.1%) | 8 (88.9%) | ||
| Segmental | 33 (34.4%) | 0 (0%) | 33 (100%) | ||
| ≤20 mm | 69 (71.9%) | 6 (8.7%) | 63 (91.3%) | >0.05 | |
| >20 mm | 13 (13.5%) | 1 (7.7%) | 12 (92.3%) | ||
| NA | 14 (14.6%) | 0 (0%) | 14 (100%) | ||
Figure 1Surgical and pathological management of specimen and margins during and after PM